Press Releases

Alfa Chemistry Materials Offers Wide Options of Resins for Decoration or Manufacture of Plastics

AI & Medicine’s Drug Research and Development Platform Assists Biomarker Discovery

Study Shows Proof of Concept of BioIVT HEPATOPAC Cultures with Targeted Assay to Evaluate Bioactivation Potential and Drug-induced Liver Injury (DILI) Risk

New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment

WCG Leads the Way and Sets a New Standard - Announcing the Formation of WCG IRB and the Launch of New WCG IRB Connexus™

WCG has unified its five IRBs – Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, New England IRB, and Aspire IRB – in a single brand, WCG IRB. It has also launched a new technology – WCG IRB Connexus – to support clients’ ethical review submissions and management. Further information is available on it new website at www.wcgirb.com.

First Databank Selected as Drug Database Provider for CliniComp, Intl.’s Full-Service EHR Pharmacy Solution

For busy hospital clinicians making key medication decisions, minutes matter. They need up-to-the-minute reliable, authoritative drug information integrated into the EHR for better clinical decision-making at the point of care and to support alerts, interoperability and smarter data analytics. With drug information changing daily, that information also needs to be updated as soon as evidence-based knowledge and FDA guidance change--and it needs to be available immediately via the cloud rather than requiring frequent downloads. For all of those reasons, CliniComp Intl. has inked a deal with First Databank (FDB), the industry’s most trusted drug database, to drive streamlined inpatient pharmacy workflows for hospitals using the CliniComp’s EHR.

BioIVT Launches HEPATOMUNE Kit to Facilitate Liver Toxicity and Inflammation Studies for Drug Discovery and Disease Research

Applications for this model include assessing drug candidates’ hepatotoxicity, and studying inflammation-related diseases

ATMPS advanced therapy blockchain platform has successful testing with NHS partners

Alfa Chemistry Testing Lab Builds an Exclusive Regulatory Resource Section on Its Website

SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology

SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology.

New UltraPure - Advancing competitive edge for biotech and pharma

DIASORIN AND MEMED PARTNER TO DEVELOP AND COMMERCIALIZE NOVEL HOST IMMUNE RESPONSE BASED DIAGNOSTICS SOLUTION

Licensing Agreement to add MeMed BV™, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs. Viral Infections, to the broad DiaSorin LIAISON test menu, available on LIAISON analyzers

Absolute Antibody Adds SeqPack™ Hybridoma Preservation Kit to Antibody Sequencing Service

Salaso Health’s telemedicine and live exercise platform enable US healthcare teams to stay safely connected with COVID-19 patients

In the current pandemic environment, face-to-face physical therapy visits are less viable due to increasing demands on the healthcare system, as well as the enactment of stay-at-home measures and the reticence of patients particularly those from at-risk groups to visit a clinic or hospital setting.

Matexcel Offers a Wide Selection of Natural Materials for Research Needs

Lifeasible Provides Virus-like Particles Production in Plant

Profacgen Provides Data Analysis Service for Biological Discovery

Phase 2/3 trial suggests that AMZELL’s new topical treatment (AMZ001) for the treatment of knee osteoarthritis symptoms is effective

The phase 2/3 trial of AMZ001, a novel once daily topical diclofenac formulation, provides efficacy and safety results in the relief of pain associated with knee osteoarthritis (OA)

Maravai LifeSciences Expands TriLink BioTechnologies CleanCap® mRNA Capping Capacity and Adds New Plasmid DNA Manufacturing

Maravai LifeSciences has expanded TriLink BioTechnologies CleanCap® mRNA capping capacity and added new Plasmid DNA manufacturing. It is TriLink’s second manufacturing expansion within a year and will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical-grade APIs to include mRNA, self-amplifying RNA and plasmid DNA.

Panthera further extends its network of clinical trial sites with the opening of a clinical trial site in North London in collaboration with Medicus Health Partners

• Panthera’s network of UK clinical trials sites grows to seven with several others in development.

BOC Sciences Launched Its PROTACs Technology Platform to Assist Drug Development